Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
San Raffaele University of Rome · Frontier Science Foundation-Hellas · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
611
total citations
- FWCI
- 33.64
- Percentile
- 100%
- References
- 25
Citations per year
Authors
25Topics & keywords
Topics
Keywords
- Trastuzumab
- Medicine
- Internal medicine
- Interim analysis
- Breast cancer
- Oncology
- Clinical endpoint
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.